[OK-432 therapy for lymphangioma in children].
OBJECTIVE
To report the experience with OK-432 therapy for lymphangioma in children.


METHODS
Retrospective study of 19 children with lymphangioma treated with OK-432 in Ribeirão Preto, state of São Paulo, Brazil, between 1999 and 2003.


RESULTS
All patients presented response to OK-432, 12 had total shrinkage and seven had partial shrinkage varying from 50 to 80%. Patients had fever after injections of OK-432 for 2 to 10 days, no damage to the overlying skin was observed.


CONCLUSIONS
OK- 432 is safe, effective and can be used as primary choice of treatment of patients with lymphangiomas because of the excellent response. In these cases surgery should not be necessary. In patients with partial regression new injections of OK-432 must be used to shrink the lesion. Thereby safely surgery could be made.
Ruiz
Everaldo
E
Departmento de Puericultura e Pediatria do Hospital das Clínicas da Faculdade de Medicina de Riberião Preto, Universidade de São Paulo, Ribeirao Preto, SP. lgtone@fmrp.usp.br
Valera
Elvis T
ET
Veríssimo
Francisco
F
Tone
Luiz G
LG
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008202:Lymphangioma / Q000188:drug therapy*; D010844:Picibanil / Q000627:therapeutic use*; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D010844:Picibanil